#Epilepsy #Surgery #LITT #Neurology #Neurosurgery
Mesial temporal lobe epilepsy (mTLE) is the most common form of
drug-resistant focal epilepsy, affecting approximately one-third of epilepsy
patients. This condition is characterized by recurrent seizures that do not
respond to standard antiepileptic treatments, significantly impacting patients'
quality of life.
The standard treatment for drug-resistant cases remains anterior
temporal lobectomy (ATL), a surgical procedure that removes the brain
region responsible for seizures. This approach has demonstrated high efficacy,
with a significant rate of seizure freedom. However, it is associated with
post-operative risks, including neurocognitive impairments, memory deficits,
and risks of infections or hemorrhages. Additionally, not all patients are
eligible for this surgery due to the location of epileptic foci or the presence
of comorbidities.
Given these limitations, less invasive alternatives have emerged,
including laser interstitial thermal therapy (LITT), radiofrequency
ablation (RFA), and stereotactic radiosurgery (SRS). These
techniques aim to selectively destroy epileptogenic foci while minimizing
damage to healthy brain tissue. LITT, in particular, uses an MRI-guided laser
fiber to generate targeted hyperthermia, inducing cellular necrosis and
reducing epileptic activity. Compared to conventional surgery, this minimally
invasive approach offers reduced recovery time and fewer post-operative
complications while showing promising efficacy in seizure control.
This study explores the efficacy and safety of LITT, RFA, and SRS
in the treatment of drug-resistant temporal epilepsy.
Read next: Monotherapy for Pediatric Focal Epilepsy: Levetiracetam vs. Carbamazepine, Which is the Better Option?
LITT: A promising alternative?
A total of 42 studies including 1,675 patients with mTLE
were analyzed. Among them, 1,303 underwent LITT, 188 underwent RFA,
and 184 received SRS. The effectiveness of these techniques was assessed
based on the following outcome variables: seizure freedom rate (Engel classification), major complication rate, and reoperation rate.
The results indicate that LITT stands out in terms of efficacy and
safety compared to other minimally invasive techniques. In terms of seizure
control, LITT achieved the highest seizure freedom rate (55.0%),
followed closely by SRS (53.8%) and RFA (46.3%). Patients with
hippocampal sclerosis responded particularly well to LITT, suggesting an
optimized potential for this subgroup.
Regarding safety, LITT had the lowest major complication rate
(2.3%), significantly lower than SRS (14.3%) and RFA (3.9%).
The reoperation rate followed a similar trend: 14.3% for LITT,
compared to 15.4% for SRS and 28.6% for RFA, confirming the long-term
effectiveness of LITT and its advantage in reducing the need for additional
surgical interventions.
These findings position LITT as an effective and safe alternative
to existing minimally invasive techniques, offering a viable option for
patients seeking less invasive solutions than conventional surgery.
Read next: Promoting medication compliance in children with epilepsy: a cross-sectional survey
Towards a minimally Invasive revolution in epilepsy treatment
mTLE is one of the most common forms of drug-resistant focal epilepsy.
When medications fail, conventional surgery, particularly ATL, is often the
recommended approach. However, this invasive method carries post-operative
risks and may lead to cognitive or neurological deficits. In response to
these challenges, minimally invasive techniques such as LITT are emerging as
promising alternatives.
This study aimed to evaluate the efficacy and safety of LITT compared
to other minimally invasive techniques, such as RFA and SRS. By analyzing
seizure control rates, post-operative complications, and the need for
reoperation, the study sought to better position LITT in the therapeutic
arsenal for mTLE.
The results show that LITT provides effective seizure control,
with a competitive seizure freedom rate compared to other minimally
invasive approaches. Its safety profile is also favorable, with lower
complication rates and reduced need for reintervention. These
factors make LITT an effective and less invasive alternative to conventional
surgery, especially for patients looking to avoid major surgical
procedures.
However, certain limitations must be considered. The lack of direct
comparative studies between LITT and anterior temporal lobectomy limits
the scope of the conclusions, especially since the current data primarily
come from retrospective studies. Prospective and randomized clinical
trials will be necessary to confirm these findings and better define the
indications for LITT. The integration of technologies such as intraoperative
MRI and Artificial Intelligence to analyze therapeutic responses could
further enhance its effectiveness.
If these advancements materialize, LITT could become a preferred
alternative for patients with drug-resistant mTLE, offering a more
targeted and less invasive treatment option.
Read next: Predicting Amyloid: AI for Early Detection
